- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00909532
Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older With the G551D Mutation (STRIVE)
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of VX-770 in Subjects With Cystic Fibrosis and the G551D Mutation
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This was a phase 3 study in subjects with cystic fibrosis (CF) age 12 years and older who have a G551D-CFTR mutation and percent predicted forced expiratory volumn in 1 second (FEV1) between 40% and 90%.
Based on in vitro studies and pharmacologic, pharmacokinetic (PK), and safety profiles, ivacaftor was selected for clinical development as a possible treatment for patients with CF. Patients with the G551D mutation were the targeted population for this study because ivacaftor is a potentiator of the gating function of the CFTR protein, and the most prevalent mutation with a gating defect in CF is the G551D mutation.
This study was designed to further evaluate the efficacy of ivacaftor in subjects with CF who have a G551D-CFTR gene mutation and to evaluate safety in this population over a longer period than previously studied.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 3
Kontakter och platser
Studieorter
-
-
New South Wales
-
Westmead, New South Wales, Australien, 2145
- The Children's Hospital Westmead
-
-
Queensland
-
Chermside, Queensland, Australien, 4032
- The Prince Charles Hospital
-
Herston, Queensland, Australien, 4026
- Royal Children's Hospital Brisbane
-
South Brisbane, Queensland, Australien, 4101
- Mater Adult Hospital
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Royal Children's Hospital Melbourne
-
-
Western Australia
-
Nedlands, Western Australia, Australien, 6009
- Lung Institute of Western Australia
-
Subiaco, Western Australia, Australien, 6008
- Princess Margaret Hospital for Children
-
-
-
-
-
Paris, Frankrike, 75014
- Hôpital Cochin
-
Paris, Frankrike, 75015
- Hopital Necker
-
Roscoff, Frankrike, 29684
- Centre de Perharidy
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35233-1711
- University of Alabama
-
-
California
-
Oakland, California, Förenta staterna, 94611
- Kaiser Permanente Medical Care Program
-
Palo Alto, California, Förenta staterna, 94304
- Cystic Fibrosis Research Office, Stanford University
-
San Diego, California, Förenta staterna, 92123-5070
- Rady Children's Hospital
-
-
Colorado
-
Denver, Colorado, Förenta staterna, 80206
- National Jewish Medical and Research Center
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30322
- Emory Cystic Fibrosis Center
-
-
Idaho
-
Boise, Idaho, Förenta staterna, 83712
- St. Luke's CF Clinic
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60614
- Children's Memorial Hospital
-
-
Indiana
-
Indianapolis, Indiana, Förenta staterna, 46202
- Indiana University
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- University of Iowa
-
-
Maryland
-
Baltimore, Maryland, Förenta staterna, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Förenta staterna, 02115
- Children's Hospital Boston
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48109
- University of Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55455
- Pulmonary, Allergy & Critical Care Medicine, University of Minnesota
-
-
Missouri
-
Kansas City, Missouri, Förenta staterna, 64108
- The Children's Mercy Hospital
-
St. Louis, Missouri, Förenta staterna, 63110
- Washington University
-
-
Nebraska
-
Omaha, Nebraska, Förenta staterna, 68198-5300
- Adult Pulmonary/ CF, University of Nebraska Medical Center
-
-
New Jersey
-
Long Branch, New Jersey, Förenta staterna, 07740
- Monmouth Medical Center
-
-
New York
-
Buffalo, New York, Förenta staterna, 14222
- Women and Children's Hospital of Buffalo
-
New Hyde Park, New York, Förenta staterna, 11042
- Long Island Jewish Medical Center
-
Syracuse, New York, Förenta staterna, 13210
- SUNY Upstate Medical University
-
-
North Carolina
-
Chapel Hill, North Carolina, Förenta staterna, 27599
- University of North Carolina at Chapel Hill
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Förenta staterna, 44106
- Pediatric & Pulmonary Division, Rainbow Babies/Case Western
-
Columbus, Ohio, Förenta staterna, 43205
- Nationwide Children's Hospital
-
Toledo, Ohio, Förenta staterna, 43606
- Toledo Children's Hospital
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97239-3098
- Oregon Health & Sciences University
-
-
Pennsylvania
-
Hershey, Pennsylvania, Förenta staterna, 17033
- Hershey Medical Center
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- Children's Hospital of Philadelphia
-
Pittsburgh, Pennsylvania, Förenta staterna, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Tennessee
-
Knoxville, Tennessee, Förenta staterna, 37916
- East Tennessee Children's Hospital
-
Nashville, Tennessee, Förenta staterna, 37232-5735
- Vanderbilt University Medical Center
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84132
- University of Utah
-
-
Virginia
-
Charlottesville, Virginia, Förenta staterna, 22908
- University of Virginia
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98105
- Seattle Children's Hospital
-
Seattle, Washington, Förenta staterna, 98195-6522
- Division of Pulmonary and CCM, University of Washington
-
-
West Virginia
-
Morgantown, West Virginia, Förenta staterna, 26506
- West Virginia University
-
-
Wisconsin
-
Milwaukee, Wisconsin, Förenta staterna, 53226
- Medical College of Wisconsin
-
-
-
-
-
Cork, Irland
- Cork University Hospital
-
Dublin, Irland, 9
- Beaumont Hospital
-
Dublin, Irland, 4
- St. Vincent's University Hospital
-
Dublin, Irland, 12
- Our Lady's Children's Hospital
-
Dublin, Irland, 24
- The National Children's Hospital
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3H 3A7
- Queen Elizabeth Ii Health Sciences Centre
-
-
Ontario
-
Toronto, Ontario, Kanada, M5B 1W8
- St. Michael's Hospital
-
Toronto, Ontario, Kanada, M5G 1X8
- CF Center, Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Montreal Children's Hospital - MUHC
-
-
-
-
-
London, Storbritannien, SW3 6LR
- Imperial College London
-
-
Northern Ireland
-
Belfast, Northern Ireland, Storbritannien, BT9 7AB
- Belfast City Hospital
-
-
-
-
-
Prague, Tjeckien, 15006
- FN Motol
-
-
-
-
-
Erlangen, Tyskland, 91054
- Kinder- und Jugendklinik Universitätsklinikum Erlangen
-
Jena, Tyskland, 07740
- Mukoviszidose-Zentrum am Klinikum der Friedrich-Schiller-Universität Jena, Klinik für Kinder- und Jugendmedizin
-
Munich, Tyskland, 80337
- Klinikum der LMU München, Dr. von Haunersches Kinderspital (CHA)
-
Wurzburg, Tyskland, 97080
- Universitäts-Kinderklinik Würzburg
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Confirmed diagnosis of cystic fibrosis (CF) and G551D mutation in at least 1 allele
- Forced expiratory volume in 1 second (FEV1) of 40% to 90% (inclusive) of predicted normal for age, gender, and height at Screening.
- No clinically significant abnormalities that would have interfered with the study assessments, as judged by the investigator
- Willing to use highly effective birth control methods during the study
Exclusion Criteria:
- History of any illness or condition that might confound the results of the study or pose an additional risk in administering study drug to the subject
- Acute respiratory infection, pulmonary exacerbation, or changes in therapy for pulmonary disease within 4 weeks of Day 1 of the study
- History of alcohol, medication or illicit drug abuse within one year prior to Day 1
- Abnormal liver function ≥ 3x the upper limit of normal
- Abnormal renal function at Screening
- History of solid organ or hematological transplantation
- Pregnant, planning a pregnancy, breast-feeding, or unwilling to follow contraception requirements
- Ongoing participation in another therapeutic clinical study or prior participation in an investigational drug study within 30 days prior to Screening
- Use of inhaled hypertonic saline treatment
- Concomitant use of any inhibitors or inducers of cytochrome P450 3A4 (CYP 3A4)
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Placebo-jämförare: Placebo
Försökspersoner som fick placebo var 12:e timme (q12h) i upp till 48 veckor.
|
Tablett ges oralt var 12:e timme i upp till 48 veckor
|
Experimentell: 150 mg Ivacaftor q12h
Försökspersoner som fick 150 mg ivacaftor var 12:e timme i upp till 48 veckor.
|
150-mg tablets given orally q12h for up to 48 weeks
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Absolute Mean Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24
Tidsram: baseline through 24 weeks
|
Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.
|
baseline through 24 weeks
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Absolut förändring från baslinjen i svettkloridkoncentration till och med vecka 24 och vecka 48
Tidsram: baseline genom 24 veckor och 48 veckor
|
Svettkloridtestet (kvantitativ pilokarpinjontofores) är ett standardverktyg för diagnostik för cystisk fibros (CF), som fungerar som en indikator på aktiviteten för cystisk fibros transmembrankonduktansregulator (CFTR).
|
baseline genom 24 veckor och 48 veckor
|
Absolut förändring från baslinjen i vikt vid vecka 24 och vecka 48
Tidsram: baseline till 24 veckor och 48 veckor
|
Eftersom undernäring är vanligt hos patienter med cystisk fibros (CF) på grund av ökad energiförbrukning på grund av lungsjukdom och fettmalabsorption, är kroppsvikt ett viktigt kliniskt mått på näringsstatus.
|
baseline till 24 veckor och 48 veckor
|
Absolute Mean Change From Baseline in Percent Predicted FEV1 Through Week 48
Tidsram: baseline through 48 weeks
|
Spirometry (as measured by FEV1) is a standardized assessment to evaluate lung function that is the most widely used endpoint in cystic fibrosis studies.
|
baseline through 48 weeks
|
Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Score Through Week 24 and Week 48 (Respiratory Domain Score, Pooled)
Tidsram: baseline through 24 weeks and 48 weeks
|
The CFQ-R is a health-related quality of life measure for subjects with cystic fibrosis.
Each domain is scored from 0 (worst) to 100 (best).
A difference of at least 4 points in the respiratory domain score of the CFQ-R is considered a minimal clinically important difference (MCID).
|
baseline through 24 weeks and 48 weeks
|
Time-to-first Pulmonary Exacerbation Through Week 24 and Week 48
Tidsram: baseline through 24 weeks and 48 weeks
|
Pulmonary exacerbation was defined as a change in antibiotic therapy (intravenous, inhaled, or oral) for any 4 or more of signs/symptoms such as change in sputum; new or increased hemoptysis; increased cough or dyspnea; malaise, fatigue, or lethargy; temperature above 38 degrees C; anorexia or weight loss; sinus pain/tenderness and discharge; change in physical examination of the chest; decreased pulmonary function by 10%; and radiographic changes indicative of pulmonary infection.
|
baseline through 24 weeks and 48 weeks
|
Samarbetspartners och utredare
Samarbetspartners
Utredare
- Huvudutredare: Bonnie W. Ramsey, MD, Children's Hospital and Regional Medical Center, Seattle, Washington, USA
- Huvudutredare: Stuart Elborn, MD, Respiratory Medicine Group, Queen's University of Belfast, Belfast, Northern Ireland, UK
Publikationer och användbara länkar
Allmänna publikationer
- Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordonez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.
- Flume PA, Wainwright CE, Elizabeth Tullis D, Rodriguez S, Niknian M, Higgins M, Davies JC, Wagener JS. Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor. J Cyst Fibros. 2018 Jan;17(1):83-88. doi: 10.1016/j.jcf.2017.06.002. Epub 2017 Jun 24.
- Solem CT, Vera-Llonch M, Liu S, Botteman M, Castiglione B. Impact of pulmonary exacerbations and lung function on generic health-related quality of life in patients with cystic fibrosis. Health Qual Life Outcomes. 2016 Apr 21;14:63. doi: 10.1186/s12955-016-0465-z.
- Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione B, Vera-Llonch M. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015 Jul 2;13:93. doi: 10.1186/s12955-015-0293-6.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- VX08-770-102
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Cystisk fibros
-
Igdir UniversityOkan UniversityRekryteringDiet, hälsosam | Acne CysticKalkon
-
University of MichiganNational Cancer Institute (NCI); National Institutes of Health (NIH)AvslutadBröstcancer | Mass Cystic | Godartad massaFörenta staterna
-
National Institute of Allergy and Infectious Diseases...Avslutad
-
ProgenaBiomeRekryteringAcne vulgaris | Acne | Acne rosacea | Acne Inversa | Akne Keloidalis | Akne Keloid | Acne Conglobata | Acne Cystic | Acne Pomade | Acne Indurata | Acne Papular | Acne Tropica | Acne Urticata | Acne Fulminans | Akne follikulär | Acne Tropicalis | Acne Detergicans | Akne Jodid | Acne VarioliformisFörenta staterna
Kliniska prövningar på Placebo
-
SamA Pharmaceutical Co., LtdOkändAkut bronkit | Akut övre luftvägsinfektionKorea, Republiken av
-
National Institute on Drug Abuse (NIDA)AvslutadAnvändning av cannabisFörenta staterna
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAvslutadManliga försökspersoner med typ II-diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedAvslutadFarmakokinetik | SäkerhetsfrågorStorbritannien
-
Regado Biosciences, Inc.AvslutadFrisk volontärFörenta staterna
-
Texas A&M UniversityNutraboltAvslutadGlucose and Insulin Response
-
Longeveron Inc.AvslutadHypoplastiskt vänsterhjärtsyndromFörenta staterna
-
ItalfarmacoAvslutadBeckers muskeldystrofiNederländerna, Italien
-
West Penn Allegheny Health SystemAvslutadAstma | Allergisk rinitFörenta staterna